On the continent, French group Sanofi fell 3.3 per cent and Swiss giants Roche and Novartis shed 2.2 per cent and 1.1 per ...

Fitting in a workout after a long day of sitting at a desk might not be enough to compensate for the impacts of sedentary ...

The project, which includes partners Onyx Equities, Russo Development and Related Fund Management, will introduce new, Class ...

When the healthcare sector sneezes, European investors catch a cold. Healthcare is the single biggest sector in the Stoxx ...

Spherix has been tracking the C3G market for over four years in both the U.S. and Europe. The studies have provided meaningful insights into physician perceptions of unmet needs and expectations for ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling ...

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...